Sublingual Format Suite

Powder, sachet, fast-dissolve tablet, film, strip, lozenge, troche, and metered-dose spray formats for rapid sublingual absorption of bioregulator compounds.

Full mechanistic definition forthcoming.

A documented format in pharmaceutical practice.

Historical timeline of the delivery format in the pharmaceutical literature — first characterization, commercial precedents, decades of regulatory-approved use — forthcoming.

How the format delivers.

Absorption pathway, bioavailability characteristics, first-pass metabolism considerations, onset and duration profiles — forthcoming.

Bioregulators formulated for this platform.

Tripeptide-KED, Tetrapeptide-AEDG, and Tripeptide-EDR formulated for sublingual absorption.

See the full bioregulator class and the per-compound published literature for compound-specific research references.

Classification and oversight.

Dietary supplement (21 CFR Part 111), OTC monograph, and 503A compounding pathways depending on indication and concentration.

Detailed regulatory analysis — agency-specific requirements, classification thresholds, and pathway-specific labeling considerations — forthcoming.

The format in the scientific literature.

PubMed-indexed peer-reviewed references establishing the format as legitimate pharmaceutical science — forthcoming.

The Atumnus Sublingix™ platform.

The Sublingix™ platform is the Atumnus patent-pending embodiment of Sublingual Format Suite. It is licensed to operating affiliates for commercial development across the Opticeutical and Endoceutical tiers, and is one of the branded delivery technologies that anchors the Atumnus intellectual-property estate.

The Sublingix™ trademark and associated patent-pending technology are held by Atumnus LLC, the founding entity of endogenic pharmacology. See affiliated entities for institutional structure.

Adjacent delivery formats.

Within the same cluster (Oral and Mucosal Delivery), see the full set of delivery platforms in this category.

← Back to all delivery platforms